Should Delta-8 THC Be Regulated? 'It's A Total Free-For-All,' Says Industry Expert

The rise of Delta-8 THC, a hemp-derived cannabinoid, has ignited debate within the cannabis industry about its regulation.

Will Muecke, co-founder of Artemis Growth Partners, addressed this issue during an exclusive interview with Benzinga, urging tighter controls on synthetic cannabinoids.

Muecke, an upcoming speaker for the Benzinga Cannabis Capital Conference, discussed the regulatory challenges surrounding Delta-8 THC and the need for reform.

Demand for Regulation and Testing

Muecke did not mince words when discussing the current state of the Delta-8 THC market: "Any synthetic derivative that’s an intoxicating agent that’s going in the body, it should be tested, and it should be regulated.”

Muecke's comments align with the increasing call for reform within the cannabis industry, where the lack of consistent regulation has allowed the widespread sale of untested products. Delta-8 THC has grown in popularity due to its legal status in some states, but without uniform safety measures, concerns about product safety continue to rise.

"We shouldn’t be having a free-for-all of Delta-8 and other synthetic derivations off the hemp market,” Muecke said.

Current Chaos in the Market

In discussing the unregulated production of Delta-8 THC, Muecke described the current state of affairs as disorganized and unsafe. "Right now, it’s a total free-for-all, and we got a bunch of folks that are making stuff in garage labs and selling it out of a website," he explained. His comments reflect concerns that the unregulated nature of these products could lead to health risks for consumers.

The absence of uniform regulations for Delta-8 THC has resulted in a fragmented market, with varying standards across states. Muecke pointed out that proper safety protocols and regulatory oversight are essential to protect consumers and maintain industry credibility.

A Unified Approach to Regulation

Muecke also called for cooperation between the hemp industry and the regulated cannabis market, which are often divided over regulatory issues like Delta-8 THC. "I think there has to be harmonization between the regulated market and the hemp lobby, and we shouldn’t be fighting each other," he said, emphasizing the importance of a unified approach to address the industry's regulatory challenges.

As Muecke prepares to speak at the Benzinga Cannabis Capital Conference, his focus on regulation and consumer safety brings attention to the broader conversation about the future of cannabis regulation in the U.S.

The Role of Science and Safety

Muecke concluded by stressing that science and safety should guide the regulatory process for synthetic cannabinoids. "Delta-8 and all of the synthetics should go away. I think science and safety should prevail, and we should regulate these markets to have free and clear access," he said. His remarks underscore the importance of implementing safety measures to ensure consumers access tested, regulated products.

Muecke's emphasis on science-backed regulations offers a clear direction for the cannabis industry as it seeks to navigate the evolving market of synthetic cannabinoids like Delta-8 THC.

Benzinga edit with images by Hannah Spray Photography and PNOIARSA on Shutterstock